Recombinetics Overview

  • Founded

  • 2008

Founded
  • Status

  • Private

  • Employees

  • 33

Employees
  • Latest Deal Type

  • Debt - PPP

  • Latest Deal Amount

  • $766K

  • Investors

  • 3

Recombinetics General Information

Description

Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative medicine. The company's technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools, enabling biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

Contact Information

Website
www.recombinetics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Other Healthcare Services
Primary Office
  • 3388 Collins Drive
  • Eagan, MN 55121
  • United States
+1 (612) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recombinetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Debt - PPP 14-Apr-2020 $766K 0000 Completed Generating Revenue
17. Later Stage VC 000.00 0000 Completed Generating Revenue
16. Grant 000.00 000.00 Completed Generating Revenue
15. Grant 01-Jan-2019 00.000 000.00 Completed Generating Revenue
14. Later Stage VC (Series A) 18-Sep-2018 000.00 000.00 Completed Generating Revenue
13. Grant 01-Jan-2018 000 000.00 Completed Generating Revenue
12. Grant 01-Jan-2017 00.000 000.00 Completed Generating Revenue
11. Grant 01-Jan-2017 00000 000.00 Completed Generating Revenue
10. Later Stage VC 14-Nov-2016 $11M $13.2M Completed Generating Revenue
9. Grant 01-Jan-2016 $1.46M $2.21M Completed Generating Revenue
To view Recombinetics’s complete valuation and funding history, request access »

Recombinetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative
Other Healthcare Technology Systems
Eagan, MN
33 As of 2023
0000
000000000 - 0000

000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
000000000 00000 (000
Milpitas, CA
00 As of 0000
000.00
0000000000 000.00

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000000000000
Ronkonkoma, NY
00 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recombinetics Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Applied StemCell Venture Capital-Backed Milpitas, CA 00 000.00 0000000000 000.00
000000000 00000000 Accelerator/Incubator Backed Ronkonkoma, NY 00 0000000000
00000000 000 Formerly VC-backed Somerville, MA 000 00000 000000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
000000000 00000000 Formerly VC-backed Durham, NC 000 00000 00000000 00000
You’re viewing 5 of 22 competitors. Get the full list »

Recombinetics Patents

  • 172

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 9

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Recombinetics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022526836-A Sterile fish Pending 09-Apr-2019 0000000000
US-20220015341-A1 Sterile fish Pending 09-Apr-2019 0000000000
US-20210251200-A1 Production method for animal models with disease associated phenotypes Pending 31-Aug-2018 00000000000
US-20190183100-A1 Animal models for polycystic kidney disease Inactive 19-Dec-2017 00000000000
US-20190045761-A1 Inducible disease models methods of making them and use in tissue complementation Inactive 11-Aug-2017 A01K67/0278
To view Recombinetics’s complete patent history, request access »

Recombinetics Executive Team (23)

Name Title Board Seat Contact Info
Rocco Morelli Chief Executive Officer
David Aberle Chief Financial Officer & Vice President of Finance
Dan Carlson Ph.D Chief Scientific Officer & Senior Vice President, Research & Development
Matt Tector Ph.D Chief Scientific Officer
Scott Fahrenkrug Ph.D Co-Founder
You’re viewing 5 of 23 executive team members. Get the full list »

Recombinetics Board Members (17)

Name Representing Role Since
Bill Farrell Self Board Member 000 0000
Corey Zarecki Self Board Member 000 0000
David Largaespada Ph.D Self Board Member 000 0000
Jerry Arndt Self Board Member 000 0000
Marylinn Munson Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Recombinetics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recombinetics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Newlin Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Recombinetics’s complete investors history, request access »

Recombinetics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 08-Oct-2020 0000000000 Other Healthcare Services 0000 0000
To view Recombinetics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial